TRANSFECTION AND EXPRESSION OF HUMAN O6-METHYLGUANINE-DNA METHYLTRANSFERASE (MGMT) CDNA IN CHINESE-HAMSTER CELLS - THE ROLE OF MGMT IN PROTECTION AGAINST THE GENOTOXIC EFFECTS OF ALKYLATING-AGENTS

被引:0
|
作者
KAINA, B [1 ]
FRITZ, G [1 ]
MITRA, S [1 ]
COQUERELLE, T [1 ]
机构
[1] OAK RIDGE NATL LAB, DIV BIOL, OAK RIDGE, TN 37831 USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
O6-Methylguanine-DNA methyltransferase (MGMT) is responsible for removal of O6-alkylguanine from DNA induced by alkylating mutagens/carcinogens. To analyze the involvement of O6-alkylguanine in the generation and MGMT in avoidance of various genotoxic effects of alkylating agents, we transfected Chinese hamster ovary (CHO) cells that lack MGMT activity with human MGMT cDNA cloned into a mammalian expression vector (pSV2MGMT). A high proportion (60-80%) of transfectants selected for a co-transfected neo gene survived treatment with high doses of N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) and N-hydroxyethyl-N-chloroethylnitrosourea (HeCNU). Parallel transfections with an expression vector containing the bacterial ada gene (pSV2ada) showed the human MGMT to be more effective than the ada expression vector in mediating alkylation resistance. Various clonal CHO cell lines have been established stably transfected with the human MGMT cDNA. The transfectants expressed human MGMT at levels ranging from 8600 to 210 000 molecules per cell. The high MGMT expressors became strongly resistant to the killing effects of MNNG. HeCNU, N-methyl-N-nitrosourea (MNU) and, to a significant lesser degree, methyl methanesulfonate (MMS) and ethyl methanesulfonate (EMS). No killing resistance was observed to N-ethyl-N-nitrosourea (ENU), though the MGMT and ada transfectants showed reduction in mutation frequency induced by this agent. Protection from mutation induction by MGMT (and ada) expression was also demonstrated for MNNG. The transfectants were also protected from the sister chromatid exchange (SCE) inducing and, to a lesser degree, clastogenic effect of MNNG and MNU, and slightly to EMS and MMS. Again no protection was observed towards ENU. Correlations between MGMT activity and resistance to a given end point suggest that, for MNNG, O6-methylguanine is the preponderant toxic, mutagenic and SCE inducing lesion. About 90% of MNNG (and MNU) induced SCEs and nearly all of the MNNG-induced gene mutations seem to be due to this adduct. For alkylation-induced chromosomal aberrations, however, and for cell killing and SCEs induced by MMS, EMS and ENU, other lesions than O6-alkylguanine appear to be of major importance. The data strongly support the view that O6-methylguanine is a genotoxic lesion and MGMT a function decisively involved in avoidance of genotoxic effects in cells exposed to MNNG and related compounds. They indicate also that it is important to take into account the property and mode of action of any given alkylating agent in assessing the protective role of MGMT against alkylation-induced genotoxicity.
引用
收藏
页码:1857 / 1867
页数:11
相关论文
共 50 条
  • [1] Gemox or Alkylating Agents in Neuroendocrine Tumors? The Help of O6-Methylguanine-DNA Methyltransferase (MGMT) Status?
    Dussol, A. S.
    Joly, M. O.
    Hervieu, V
    Forestier, J.
    Lombard-Bohas, C.
    Cassier, P.
    Scoazec, J. Y.
    Walter, T.
    NEUROENDOCRINOLOGY, 2015, 102 (1-2) : 118 - 118
  • [2] THE ORIGIN OF O6-METHYLGUANINE-DNA METHYLTRANSFERASE IN CHINESE-HAMSTER OVARY CELLS TRANSFECTED WITH HUMAN DNA
    TANO, K
    SHIOTA, S
    REMACK, JS
    BRENT, TP
    BIGNER, DD
    MITRA, S
    MUTATION RESEARCH, 1991, 255 (02): : 175 - 182
  • [3] RELATIONSHIP BETWEEN CLINICAL OUTCOME AND EXPRESSION OF O6-METHYLGUANINE-DNA METHYLTRANSFERASE (MGMT) IN MEDULLOBLASTOMA
    Kurimoto, Tomoko
    Kondo, Akihide
    Sakaguchi, Sachi
    Fujimura, Junya
    Saito, Masahiro
    Arakawa, Takashi
    Arai, Hajime
    Shimizu, Toshiaki
    NEURO-ONCOLOGY, 2014, 16 : 77 - 78
  • [4] O6-Methylguanine-DNA Methyltransferase (MGMT) mRNA Expression Predicts Outcome in Malignant Glioma Independent of MGMT Promoter Methylation
    Kreth, Simone
    Thon, Niklas
    Eigenbrod, Sabina
    Lutz, Juergen
    Ledderose, Carola
    Egensperger, Rupert
    Tonn, Joerg C.
    Kretzschmar, Hans A.
    Hinske, Ludwig C.
    Kreth, Friedrich W.
    PLOS ONE, 2011, 6 (02):
  • [5] Inactivation of O6-methylguanine-DNA methyltransferase (MGMT) by promoter hypermethylation is associated with loss of MGMT protein expression in skin cancer
    Abdel-Farrah, R
    Glick, A
    Hennings, H
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2001, 117 (02) : 473 - 473
  • [6] Effects of O6-methylguanine-DNA methyltransferase (MGMT) polymorphisms on cancer: a meta-analysis
    Zhong, Yu
    Huang, Yongsheng
    Huang, Yan
    Zhang, Tianbao
    Ma, Chengying
    Zhang, Shuyong
    Fan, Weiwei
    Chen, Hongyan
    Qian, Ji
    Lu, Daru
    MUTAGENESIS, 2010, 25 (01) : 83 - 95
  • [7] O6-methylguanine-DNA methyltransferase expression in human retinoblastoma: implications for treatment with alkylating agents.
    Choy, KW
    Lam, DSC
    Yu, C
    Fan, DSP
    Li, WWY
    Pang, CP
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2000, 41 (04) : S953 - S953
  • [8] Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours
    McCormack, Ann I.
    McDonald, Kerrie L.
    Gill, Anthony J.
    Clark, Susan J.
    Burt, Morton G.
    Campbell, Kirsten A.
    Braund, Wilton J.
    Little, Nicholas S.
    Cook, Raymond J.
    Grossman, Ashley B.
    Robinson, Bruce G.
    Clifton-Bligh, Roderick J.
    CLINICAL ENDOCRINOLOGY, 2009, 71 (02) : 226 - 233
  • [9] Prognostic significance of O6-methylguanine-DNA methyltransferase (MGMT) protein expression in adult anaplastic gliomas
    Brell, M
    Tortosa, A
    Acebes, JJ
    Gil, JM
    Ribalta, T
    Verger, E
    Villà, S
    Viñolas, N
    Ferrer, I
    Graus, F
    NEURO-ONCOLOGY, 2005, 7 (03) : 326 - 326
  • [10] Expression of O6-methylguanine-DNA methyltransferase (MGMT) as a mechanism of resistance to 6-thioguanine in human malignant melanoma.
    Gopas, J
    Gefen, N
    Galron, D
    Priel, E
    Brkic, G
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9126S - 9126S